
    
      This will be a single-centre, randomised, double blind, placebo controlled, two-way crossover
      study in healthy male and female subjects. There will be two treatment periods each
      consisting of 7 days. During each treatment period subjects will receive single doses of
      ketoconazole or placebo on the morning of days 1-6 with a single dose of GW642444M on the
      morning of Day 5.
    
  